GW Pharmaceuticals Stock Rises 6% After Positive CBD Drug Trial

Original Source: GW Pharmaceuticals stock rises 6% after positive CBD drug trial

GW Pharmaceuticals PLC GWPH, +2.62% said late Monday that it had a positive phase-three trial result for its Epidiolex drug. GW stock rose more than 7% in after-hours trading. Epidiolex is a drug that contains cannabidiol, or CBD, a compound found in cannabis plants. The drug is an anti-epilepsy medication and the phase-three trial was performed on 224 patients in six countries. GW said it was the fifth consecutive positive trial for Epidiolex. GW stock has gained 28% in the past year, as the S&P 500 index SPX, -0.45% rose 11%.

Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.

This article was republished on CBDNewsFeed.com from the original article, GW Pharmaceuticals stock rises 6% after positive CBD drug trial, which was originally published on 2019-05-06 12:15:00 (based on the date that was listed on the original article at the time it was republished). We shared this article on CBDNewsFeed.com because our editorial staff believed that its context was useful and helpful to our readers. If you have any questions regarding this article, please email us at [email protected].

Thank you for reading this article! We’d love to hear your thoughts and answer your questions in the comments below.

Read the original article at GW Pharmaceuticals stock rises 6% after positive CBD drug trial

GW Pharmaceuticals stock rises 6% after positive CBD drug trial

RECOMMENDED FOR YOU

Leave a Reply